---
pmid: '26403645'
title: Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular
  carcinoma cells.
authors:
- Sun X
- Ou Z
- Chen R
- Niu X
- Chen D
- Kang R
- Tang D
journal: Hepatology
year: '2016'
full_text_available: false
pmcid: PMC4688087
doi: 10.1002/hep.28251
---

# Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
**Authors:** Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D
**Journal:** Hepatology (2016)
**DOI:** [10.1002/hep.28251](https://doi.org/10.1002/hep.28251)
**PMC:** [PMC4688087](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688087/)

## Abstract

1. Hepatology. 2016 Jan;63(1):173-84. doi: 10.1002/hep.28251. Epub 2015 Nov 26.

Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in 
hepatocellular carcinoma cells.

Sun X(1), Ou Z(1), Chen R(2), Niu X(1), Chen D(1), Kang R(2), Tang D(1)(2).

Author information:
(1)Center for DAMP Biology, The Third Affiliated Hospital of Guangzhou Medical 
University, Guangzhou, Guangdong, China.
(2)Department of Surgery, University of Pittsburgh Cancer Institute, University 
of Pittsburgh, Pittsburgh, PA.

Ferroptosis is a recently recognized form of regulated cell death caused by an 
iron-dependent accumulation of lipid reactive oxygen species. However, the 
molecular mechanisms regulating ferroptosis remain obscure. Here, we report that 
nuclear factor erythroid 2-related factor 2 (NRF2) plays a central role in 
protecting hepatocellular carcinoma (HCC) cells against ferroptosis. Upon 
exposure to ferroptosis-inducing compounds (e.g., erastin, sorafenib, and 
buthionine sulfoximine), p62 expression prevented NRF2 degradation and enhanced 
subsequent NRF2 nuclear accumulation through inactivation of Kelch-like 
ECH-associated protein 1. Additionally, nuclear NRF2 interacted with 
transcriptional coactivator small v-maf avian musculoaponeurotic fibrosarcoma 
oncogene homolog proteins such as MafG and then activated transcription of 
quinone oxidoreductase-1, heme oxygenase-1, and ferritin heavy chain-1. 
Knockdown of p62, quinone oxidoreductase-1, heme oxygenase-1, and ferritin heavy 
chain-1 by RNA interference in HCC cells promoted ferroptosis in response to 
erastin and sorafenib. Furthermore, genetic or pharmacologic inhibition of NRF2 
expression/activity in HCC cells increased the anticancer activity of erastin 
and sorafenib in vitro and in tumor xenograft models.
CONCLUSION: These findings demonstrate novel molecular mechanisms and signaling 
pathways of ferroptosis; the status of NRF2 is a key factor that determines the 
therapeutic response to ferroptosis-targeted therapies in HCC cells.

Â© 2015 by the American Association for the Study of Liver Diseases.

DOI: 10.1002/hep.28251
PMCID: PMC4688087
PMID: 26403645 [Indexed for MEDLINE]
